Xenotransfusion using red blood cells from genetically modified pigs: Current preclinical research status and clinical application prospects
Vox Sanguinis · 16.11.2026
DOI: 10.1111/vox.70413 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vox Sanguinis, online erschienen am 16.11.2026. Verfasst von Juhye Roh und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Republic of Korea. Die Arbeit nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Institute of Civil Military Technology Cooperation, The Defense Acquisition Program Administration and Ministry of Trade, Industry and Energy of Korean government.
Abstract (Originalsprache)
Aging of population and emerging infectious diseases increasingly threaten stable blood supply, underscoring the need for alternative blood sources. Porcine red blood cells (pRBCs) offer notable advantages over human RBCs, including morphological and physiological similarity, established pathogen‐free breeding systems, and freedom from ABO‐ and Rh‐compatibility constraints. Recent advances in gene editing have enabled triple‐knockout (TKO) pigs lacking the three major xenoantigens recognized by human natural antibodies, reviving interest in xenotransfusion as a potential solution to blood shortages. This narrative review examines preclinical and translational studies on pRBC xenotransfusion, focusing on immunological compatibility, in vivo survival, and adverse reactions across nonhuman primate (NHP) models, genetic engineering strategies, and emerging regulatory frameworks. In Old World NHP studies, TKO pRBCs corrected acute anemia but were cleared within 24–72 h, and retransfusion elicited acute hemolytic reactions from antibody formation. Rapid, multifactorial, immune‐mediated clearance of pRBCs remains the principal barrier to clinical use, currently limiting application to emergencies such as acute massive hemorrhage. Future strategies include engineering pigs that express human complement‐regulatory proteins and applying immunomodulatory regimens to prolong pRBC survival. Although a dedicated regulatory framework for xenotransfusion is still lacking, recent clearance of pig‐organ xenotransplantation trials offers important precedent. Continued progress in genetic engineering and immunosuppression may extend xenotransfusion to emergency medicine and the care of patients with rare blood types.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Republic of Korea.
ORCID-Profile: Juhye Roh, Hee Jung Kang
Förderung
- The Institute of Civil Military Technology Cooperation
- The Defense Acquisition Program Administration and Ministry of Trade, Industry and Energy of Korean government
Zitieren
APA
Roh, J., & Kang, H. J. (2026). Xenotransfusion using red blood cells from genetically modified pigs: Current preclinical research status and clinical application prospects. Vox Sanguinis. https://doi.org/10.1111/vox.70413
Vancouver
Roh J, Kang HJ. Xenotransfusion using red blood cells from genetically modified pigs: Current preclinical research status and clinical application prospects. Vox Sanguinis. 2026. doi:10.1111/vox.70413
BibTeX
@article{Roh2026,
author = {Roh, Juhye and Kang, Hee Jung},
title = {Xenotransfusion using red blood cells from genetically modified pigs: Current preclinical research status and clinical application prospects},
journal = {Vox Sanguinis},
year = {2026},
doi = {10.1111/vox.70413}
}
EUVIMED